Imatinib-Induced Serositis: A Rare Cause of Recurrent Pleural and Pericardial Effusions

Introduction: Imatinib mesylate is first line therapy for chronic phase chronic myeloid leukemia (CML). Serositis is a rare, life-threatening, imatinib-induced complication, reported in 1.3% of newly diagnosed and 2% of other chronic phase CML patients, that may result in respiratory compromise or cardiac tamponade. Case Presentation: 72-year-old-male with CML in molecular remission on imatinib presented with recurrent pleural effusions and new pericardial effusions concerning for pre-tamponade physiology, suspected to be imatinib induced serositis. Imatinib was discontinued with resolution of effusions. The patient was transitioned to nilotinib with maintenance of BCR-ABL negativity and good tolerability. Conclusion: This case highlights the importance of recognizing imatinib-induced serositis. Prompt therapy modification can prevent morbidity while maintaining molecular remission.

Authors

Institutions

Publication Details

Journal
Journal of Community Hospital Internal Medicine Perspectives
Published
2026-11-17
DOI
https://doi.org/10.55729/2000-9666.1659
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Imatinib-Induced Serositis: A Rare Cause of Recurrent Pleural and Pericardial Effusions

Ryan P. Zimmerman, Pallab Sarker, Fatima Khalid, Maya Pillai
Journal of Community Hospital Internal Medicine Perspectives
Chronic Myeloid Leukemia Treatments
article

Imatinib-Induced Serositis: A Rare Cause of Recurrent Pleural and Pericardial Effusions

Ryan P. Zimmerman, Pallab Sarker, Fatima Khalid, Maya Pillai
article en

Abstract

Introduction: Imatinib mesylate is first line therapy for chronic phase chronic myeloid leukemia (CML). Serositis is a rare, life-threatening, imatinib-induced complication, reported in 1.3% of newly diagnosed and 2% of other chronic phase CML patients, that may result in respiratory compromise or cardiac tamponade. Case Presentation: 72-year-old-male with CML in molecular remission on imatinib presented with recurrent pleural effusions and new pericardial effusions concerning for pre-tamponade physiology, suspected to be imatinib induced serositis. Imatinib was discontinued with resolution of effusions. The patient was transitioned to nilotinib with maintenance of BCR-ABL negativity and good tolerability. Conclusion: This case highlights the importance of recognizing imatinib-induced serositis. Prompt therapy modification can prevent morbidity while maintaining molecular remission.

Journal of Community Hospital Internal Medicine PerspectivesVol. 16(6)
Reading Hospital (US)
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon